ADCETRIS Takeda Pharmaceuticals Australia Pty Ltd
Product name
ADCETRIS
Accepted date
Jan-2023
Active ingredients
Brentuximab vedotin
Proposed indication
For the treatment of advanced Hodgkin lymphoma.
Application type
C (new medicine)
Publication date
Jan-23